New chemo combo targets Hard-to-Treat liver cancer

This early-phase trial tested a two-step chemotherapy approach for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. First, patients received a standard chemo mix (mFOLFIRINOX) through the veins. Then, they got a second chemo drug (floxuridine) plus dexamethasone directly into the liver artery, along with more systemic chemo. The goal was to control the cancer while limiting side effects. However, the study was stopped early after enrolling only 5 people, so we have very little data on how well it works or its safety.